MarketCap
Facebook
X
Telegram
Country |
 USA |
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ CAPITAL |
Shares |
63.2 M |
Market Cap[1] |
$ 789 M |
EBITDA (LTM) |
- |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
- |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
Translate Bio, Inc.
TBIO
|
- | - | $ 2.81 B | Nasdaq Global Select Market,SPB | USA |
 |
Trillium Therapeutics Inc.
TRIL
|
- | - | $ 1.94 B | Nasdaq Capital Market |  Canada |
 |
Trean Insurance Group
TIG
|
- | - | $ 316 M | Nasdaq Global Select Market | USA |
 |
Urovant Sciences Ltd.
UROV
|
- | - | $ 532 M | Nasdaq Global Select Market |  Britain |
 |
Acceleron Pharma Inc.
XLRN
|
- | - | $ 10.9 B | Nasdaq Global Market,SPB | USA |
 |
Zealand Pharma A/S
ZEAL
|
- | 0.52 % | $ 821 M | Nasdaq Global Select Market |  Danmark |
 |
Zogenix, Inc.
ZGNX
|
- | -4.97 % | $ 664 M | Nasdaq Global Market,SPB | USA |
 |
Yunhong International
ZGYH
|
- | 0.10 % | $ 92.2 M | Nasdaq Capital Market |  China |
 |
ZIOPHARM Oncology, Inc.
ZIOP
|
- | -7.58 % | $ 264 M | Nasdaq Global Select Market | USA |
 |
Leap Therapeutics
LPTX
|
- | 368.57 % | $ 41.9 M | Nasdaq Global Market | USA |
 |
Cortexyme
CRTX
|
- | -1.05 % | $ 67.1 M | Nasdaq Global Select Market,SPB | USA |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
SQZ Biotechnologies Company
SQZ
|
- | 57.95 % | $ 12.8 M | NYSE | USA |
 |
Aptorum Group Limited
APM
|
- | - | $ 5.72 M | Nasdaq Global Select Market | China |
 |
FSD Pharma
HUGE
|
- | 5743.5 % | $ 69.7 M | Nasdaq Capital Market | Canada |
 |
ММЦБ
GEMA
|
- | - | - | MOEX | Russia |
 |
Промомед
PRMD
|
- | - | - | MOEX | Russia |
 |
BioAtla
BCAB
|
$ 1.74 | 0.64 % | $ 102 M | Nasdaq Global Select Market | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
- | - | $ 3.85 B | Nasdaq Capital Market | USA |
 |
Brickell Biotech
BBI
|
- | -5.38 % | $ 6.06 M | Nasdaq Capital Market | USA |
 |
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | USA |
 |
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market | Canada |
 |
ADiTx Therapeutics
ADTX
|
- | - | $ 374 | Nasdaq Capital Market | USA |
 |
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market | Canada |
 |
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | USA |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | USA |
 |
Aileron Therapeutics
ALRN
|
- | 10.36 % | $ 9.8 M | Nasdaq Global Select Market | USA |
 |
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | USA |
 |
Apellis Pharmaceuticals
APLS
|
- | - | $ 5.18 B | Nasdaq Global Select Market,SPB | USA |
 |
Athira Pharma
ATHA
|
- | - | $ 269 M | Nasdaq Global Select Market | USA |
 |
Avenue Therapeutics
ATXI
|
- | -52.27 % | $ 4.45 M | Nasdaq Global Select Market | USA |
 |
AVROBIO
AVRO
|
- | 1083.1 % | $ 745 M | Nasdaq Global Select Market | USA |
 |
AstraZeneca PLC
AZN
|
- | - | $ 96.9 B | Nasdaq Global Select Market | Britain |
 |
Brainstorm Cell Therapeutics
BCLI
|
- | -2.5 % | $ 5.88 M | Nasdaq Capital Market | USA |
 |
BeiGene, Ltd.
BGNE
|
- | 0.49 % | $ 251 B | Nasdaq Global Select Market |  Cayman-islands |
 |
Bio-Path Holdings
BPTH
|
- | - | $ 100 K | Nasdaq Capital Market | USA |
 |
Cara Therapeutics
CARA
|
- | -3.03 % | $ 260 M | Nasdaq Global Market,SPB | USA |
 |
ChromaDex Corporation
CDXC
|
- | -0.88 % | $ 598 M | Nasdaq Capital Market | USA |
 |
Caladrius Biosciences
CLBS
|
- | -16.75 % | $ 25.8 M | Nasdaq Capital Market | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
- | -5.98 % | $ 34.1 M | Nasdaq Capital Market | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
- | -4.36 % | $ 27 M | Nasdaq Capital Market | USA |
 |
Diffusion Pharmaceuticals
DFFN
|
- | 11.68 % | $ 8.97 M | Nasdaq Capital Market | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
- | -5.68 % | $ 8.28 M | Nasdaq Global Market | USA |
 |
Enochian Biosciences
ENOB
|
- | - | $ 40.5 M | Nasdaq Capital Market | USA |
 |
Esperion Therapeutics
ESPR
|
- | - | $ 661 M | Nasdaq Global Market,SPB | USA |
 |
Evofem Biosciences
EVFM
|
- | 7.55 % | $ 38.1 M | Nasdaq Capital Market | USA |
 |
Eyenovia
EYEN
|
- | 49.81 % | $ 13.2 M | Nasdaq Capital Market | USA |
 |
FibroGen
FGEN
|
- | - | $ 889 M | Nasdaq Global Select Market,SPB | USA |
 |
Homology Medicines
FIXX
|
- | 0.77 % | $ 53.4 M | Nasdaq Global Select Market | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.